The Indian pharmaceutical industry directly employs five million people. Its exports reached $25.4 billion last fiscal year, yet it remains reliant on $7.2 billion in API imports. This analysis details the sector's job creation, investment, and production capacity.
Key Takeaways
- Pharma employs 5 million directly and 10 million indirectly in India 2023
- FDI in pharma sector reached USD 22 billion cumulative till FY23
- Top 10 Indian pharma companies employ 500,000 people in 2023
- India's pharma export value hit USD 25.4 billion in FY23
- Pharmaceutical exports from India grew 8.5% YoY to USD 25.39 billion in FY23
- US accounts for 31% of India's pharma exports worth USD 7.83 billion in FY23
- India's pharmaceutical market size reached USD 50 billion in 2023, growing at a CAGR of 8-10% over the past five years
- The Indian pharma sector contributes around 3.5% to the country's total merchandise exports as of FY23
- Domestic formulation market in India was valued at INR 1.89 lakh crore (USD 22.9 billion) in FY23
- India's installed capacity for APIs is 400+ facilities with 60% utilization in 2023
- India has over 3,000 drug manufacturing units, producing 50,000+ formulations
- Annual production of penicillin G in India is 25,000 tons, 50% for exports in 2023
- Pharma R&D spend in India was USD 1.7 billion in 2023, 8-10% of sales
- India filed 1,200+ patents in pharma in 2023, up 15% YoY
- Clinical trials market in India valued at USD 1.1 billion in 2023
India’s pharma industry employs millions and drives record exports, backed by major FDI and R and D growth.
Related reading
01 · Category
Employment and Investments19 stats
01
Pharma employs 5 million directly and 10 million indirectly in India 2023
02
FDI in pharma sector reached USD 22 billion cumulative till FY23
03
Top 10 Indian pharma companies employ 500,000 people in 2023
04
Skill development programs trained 100,000 pharma workers in 2023
05
Private equity investments in pharma hit USD 3.5 billion in FY23
06
Women constitute 25% of pharma workforce in India 2023
07
R&D personnel in pharma number 50,000 in India FY23
08
Contract research employs 150,000 in India 2023
09
MSME pharma firms employ 2 million across 8,000 units
10
Venture capital in biotech startups USD 1.2 billion in 2023 India
11
Govt schemes like PLI created 50,000 jobs in pharma by 2023
12
Export-oriented units employ 1 million in pharma sector FY23
13
Digital transformation upskilled 200,000 pharma employees in 2023
14
IPOs raised USD 2 billion for pharma firms in FY23 India
15
CSR spend by pharma cos on health/employment INR 5,000 crore in FY23
16
Automation reduced manual jobs by 10% but created 30,000 tech roles in 2023
17
Overseas investments by Indian pharma USD 5 billion cumulative till 2023
18
Training institutes for pharma number 1,500 with 50,000 graduates yearly
19
Debt financing for pharma capex USD 10 billion in FY23
Interpretation
Employment and Investments Interpretation
While India's pharma sector is a prolific job-creating machine, pumping out both pills and paychecks for millions, its real prescription for the future lies in its potent blend of global investment, relentless upskilling, and a growing dose of digital disruption.
02 · Category
Exports and Imports21 stats
01
India's pharma export value hit USD 25.4 billion in FY23
02
Pharmaceutical exports from India grew 8.5% YoY to USD 25.39 billion in FY23
03
US accounts for 31% of India's pharma exports worth USD 7.83 billion in FY23
04
APIs and bulk drugs exports reached USD 2.9 billion in FY23, up 12%
05
Formulations exports constituted 73% of total pharma exports at USD 18.55 billion in FY23
06
India supplied 60% of global vaccine demand for measles and DPT in 2023
07
Pharma imports into India were USD 7.2 billion in FY23, mainly APIs from China
08
Exports to Africa grew 15% to USD 2.1 billion in FY23 from India
09
UK pharma imports from India rose 10% to USD 1.2 billion in 2023
10
Brazil imported USD 800 million worth of drugs from India in 2023
11
India's share in global generics market is 20% by volume, exports to 200+ countries
12
Oncology drugs exports from India hit USD 1.5 billion in FY23
13
Cardiac therapy exports grew 11% to USD 2.8 billion in FY23
14
Anti-infectives exports valued at USD 4.2 billion, 22% of total in FY23
15
India exported 50,000+ metric tons of paracetamol in 2023
16
Pharma exports to South Africa increased 20% to USD 450 million in FY23
17
Russia imports 25% of its generics from India, USD 600 million in 2023
18
EU countries imported USD 3.5 billion pharma from India in 2023
19
India produced 60,000 tons of paracetamol annually, 40% exported in 2023
20
Vitamin C exports from India reached 15,000 tons worth USD 200 million in FY23
21
Pharma imports dependency on China for APIs is 70% by value in FY23
Interpretation
Exports and Imports Interpretation
While proudly flexing its status as the world's pharmacy—vaccinating most children against measles, treating millions with affordable generics, and sending crucial drugs from cardiac therapies to paracetamol across 200 nations—India’s pharmaceutical prowess remains uncomfortably tethered to China for the raw ingredients that make it all possible.
03 · Category
Market Size and Revenue22 stats
01
India's pharmaceutical market size reached USD 50 billion in 2023, growing at a CAGR of 8-10% over the past five years
02
The Indian pharma sector contributes around 3.5% to the country's total merchandise exports as of FY23
03
Domestic formulation market in India was valued at INR 1.89 lakh crore (USD 22.9 billion) in FY23
04
Generics account for 80% of India's pharmaceutical exports by volume in 2023
05
India's API market is projected to grow from USD 13.4 billion in 2022 to USD 22.8 billion by 2027 at a CAGR of 11.2%
06
OTC drugs segment in India grew by 12% YoY to reach INR 35,000 crore in 2023
07
Biopharmaceutical market in India expected to reach USD 12 billion by 2025
08
India's pharma industry ranks 3rd globally in terms of volume, producing 20% of global generics
09
Contract manufacturing in Indian pharma grew 15% in 2023 to USD 5 billion
10
Vaccine market in India valued at USD 2.5 billion in 2023 with 60% export share
11
Nutraceuticals market in India hit USD 8 billion in 2023, growing at 15% CAGR
12
India's pharma retail market penetration is at 65% of the population in urban areas as of 2023
13
Hospital supplies segment grew 18% to INR 45,000 crore in FY23
14
E-pharmacy sales surged 25% to USD 1.2 billion in 2023
15
Ayurvedic and herbal medicines market reached USD 10 billion in 2023
16
Chronic therapy segment dominates with 55% share of domestic market in 2023
17
Acute therapy market grew 9% YoY to INR 82,000 crore in FY23
18
India's pharma GDP contribution stands at 1.2% in 2023
19
Branded generics hold 85% of domestic sales volume in 2023
20
Unbranded generics constitute 70% of institutional sales in India FY23
21
Pharma services market valued at USD 4.5 billion in 2023, growing 12% YoY
22
Medical devices market linked to pharma reached USD 11 billion in FY23
Interpretation
Market Size and Revenue Interpretation
India's pharmaceutical industry has confidently expanded from a global generic powerhouse into a dynamic, multi-headed giant, proving that while the world's medicine cabinet may be dominated by its pills, its own domestic market is increasingly hungry for everything from biotech breakthroughs to ancient herbs and online pharmacy convenience.
More related reading
04 · Category
Production Capacity18 stats
01
India's installed capacity for APIs is 400+ facilities with 60% utilization in 2023
02
India has over 3,000 drug manufacturing units, producing 50,000+ formulations
03
Annual production of penicillin G in India is 25,000 tons, 50% for exports in 2023
04
Cefixime production capacity stands at 500 tons per year in India
05
India manufactures 80% of its domestic drug requirements domestically in 2023
06
Bulk drug parks planned with capacity for 300 APIs, investment INR 50,000 crore
07
Vaccine production capacity in India is 3 billion doses annually as of 2023
08
Oral solid dosage forms production exceeds 100 billion units per year in India
09
Injectables production capacity is 2 billion units annually in India FY23
10
Tablet production in India reached 150 billion units in 2023
11
API production for anti-diabetics is 200 tons/year in India
12
Fermentation-based API capacity is 50,000 MT in India 2023
13
Chemical synthesis API plants number 1,200 with 70% capacity utilization
14
India has 500+ biosimilar production facilities operational in 2023
15
Ophthalmic production capacity 500 million units/year in India
16
Inhaler production at 200 million units annually from India
17
India's paracetamol production capacity is 80,000 MT per annum
18
Metformin API production 50,000 tons/year in India FY23
Interpretation
Production Capacity Interpretation
India’s pharmaceutical industry operates like a meticulously stocked but somewhat cluttered global medicine cabinet, impressively self-sufficient and bursting with bulk ingredients, yet constantly planning to build more shelves for the world's growing prescription list.
05 · Category
R&D and Innovation19 stats
01
Pharma R&D spend in India was USD 1.7 billion in 2023, 8-10% of sales
02
India filed 1,200+ patents in pharma in 2023, up 15% YoY
03
Clinical trials market in India valued at USD 1.1 billion in 2023
04
25% of global ANDA filings to USFDA are from Indian companies in 2023
05
India has 500+ USFDA-approved plants for pharma manufacturing in 2023
06
Biosimilars R&D investment reached USD 500 million in FY23
07
New drug launches in India hit 1,500 in 2023, 40% first-to-market
08
Stem cell research facilities number 100+ in India with pharma tie-ups
09
AI in drug discovery adopted by 50 Indian pharma firms in 2023
10
Vaccine R&D output includes 10 new candidates in 2023 from India
11
Gene therapy trials registered 20 in India CTRI in 2023
12
CAR-T cell therapy first approval in India for pharma use in 2023
13
Pharma IT spend on R&D tools USD 200 million in FY23
14
India ranks 12th in global innovation index for pharma 2023
15
mRNA vaccine tech transferred to 5 Indian firms post-2023
16
NCD drug innovation pipeline has 300 molecules in India 2023
17
Digital twin tech in pharma R&D piloted by 10 companies in India
18
Personalized medicine R&D spend USD 150 million in FY23 India
19
3D printing for drugs prototyped in 15 labs across India 2023
Interpretation
R&D and Innovation Interpretation
India’s pharma industry is quietly building an innovation juggernaut, where spending just 8-10% of sales on R&D somehow yields a quarter of the world’s generic filings, a surge in patents and trials, and a homegrown CAR-T approval, proving it’s possible to be both the world’s pharmacy and its clever new lab.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lars Eriksen. (2026, February 13). Indian Pharma Industry Statistics. Gitnux. https://gitnux.org/indian-pharma-industry-statistics
MLA
Lars Eriksen. "Indian Pharma Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/indian-pharma-industry-statistics.
Chicago
Lars Eriksen. 2026. "Indian Pharma Industry Statistics." Gitnux. https://gitnux.org/indian-pharma-industry-statistics.
Sources & references
78 datasets cited across this report · attribution is report-level
+1 additional datasets cited (not shown individually)